atirmociclib

Atirmociclib is a selective, orally administered small molecule inhibitor of cyclin-dependent kinase 4 (CDK4), developed by Pfizer for the treatment of various solid tumors, with a primary focus on breast cancer. By binding to the active sites of CDK4 and CDK6, atirmociclib blocks their interaction with cyclin D, leading to cell cycle arrest in the G1 phase and preventing cancer cell proliferation. The drug is currently in Phase 3 clinical trials for HER2-negative breast cancer and has also been studied in other solid tumors such as prostate cancer, liposarcoma, non-small-cell lung cancer (NSCLC), colorectal cancer, and adenocarcinoma. Atirmociclib is being evaluated both as monotherapy and in combination regimens targeting resistance mechanisms to existing CDK4/6 inhibitors[1][2][3][4][5][6].

Brand names

atirmociclib

Other names

CDK4 inhibitor PF-07220060CDK-4 inhibitor PF-07220060CDK 4 inhibitor PF-07220060